Progress in diagnosis and treatment of pediatric sepsis
-
摘要: 脓毒症是全球范围内造成儿童死亡的重要因素之一。儿童脓毒症的病原学特点、临床表现及治疗手段与成人脓毒症不尽相同，故详细了解儿童脓毒症的特点有助于早期识别和集束化管理脓毒症，从而进一步改善脓毒症患儿的预后，降低病死率。Abstract: Sepsis is one of leading causes of mortality for children all over the world. Differences in etiology, clinical presentation, and therapeutic approaches exist between children and adults. Therefore, a detailed understanding of the characteristics of children sepsis is helpful for early identification and cluster management of sepsis, which can further improve the prognosis of children with sepsis and reduce their mortality.
-
-
[1] RUDD K E, JOHNSON S C, AGESA K M, et al. Global, regional, and national Sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020, 395(10219): 200-211. doi: 10.1016/S0140-6736(19)32989-7
[2] FLEISCHMANN-STRUZEK C, GOLDFARB D M, SCHLATTMANN P, et al. The global burden of paediatric and neonatal sepsis: a systematic review[J]. Lancet Respir Med, 2018, 6(3): 223-230. doi: 10.1016/S2213-2600(18)30063-8
[3] SCHULLER K A, HSU B S, THOMPSON A B. The rate of Sepsis in a national pediatric population, 2006 to 2012[J]. Clin Pediatr, 2017, 56(11): 1001-1007. doi: 10.1177/0009922817702940
[4] WEISS S L, PETERS M J, ALHAZZANI W, et al. Surviving Sepsis campaign international guidelines for the management of septic shock and Sepsis-associated organ dysfunction in children[J]. Pediatr Crit Care Med, 2020, 21(2): e52-e106.
[5] WEISS S L, FITZGERALD J C, PAPPACHAN J, et al. Global epidemiology of pediatric severe sepsis: the Sepsis prevalence, outcomes, and therapies study[J]. Am J Respir Crit Care Med, 2015, 191(10): 1147-1157. doi: 10.1164/rccm.201412-2323OC
[6] XIAO C, WANG S, FANG F, et al. Epidemiology of pediatric severe sepsis in main pediatric intensive care unit centers in southwest China[J]. Pediatr Crit Care Med, 2019, 20(12): 1118-1125.
[7] SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. doi: 10.1001/jama.2016.0287
[8] SEYMOUR C W, LIU V X, IWASHYNA T J, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for Sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 762-774. doi: 10.1001/jama.2016.0288
[9] MATICS T J, SANCHEZ-PINTO L N. Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the Sepsis-3 definitions in critically ill children[J]. JAMA Pediatr, 2017, 171(10): e172352. doi: 10.1001/jamapediatrics.2017.2352
[10] LU Q, ZHOU M, TU Y, et al. Pathogen and antimicrobial resistance profiles of culture-proven neonatal sepsis in Southwest China, 1990-2014[J]. J Paediatr Child Health, 2016, 52(10): 939-943. doi: 10.1111/jpc.13278
[11] 北京地区PICU脓毒症调查协作组. 北京地区两家医院儿科重症监护病房486例脓毒症分析[J]. 中华儿科杂志, 2012, 50(3): 178-183. doi: 10.3760/cma.j.issn.0578-1310.2012.03.005 [12] 张卉, 冯永文, 姚咏明. 深刻理解烧创伤脓毒症发病机制的网络效应[J]. 中华医学杂志, 2020, 100(12): 881-885. doi: 10.3760/cma.j.cn112137-20191129-02603 [13] JONES S L, ASHTON C M, KIEHNE L, et al. Reductions in Sepsis mortality and costs after design and implementation of a nurse-based early recognition and response program[J]. Jt Comm J Qual Patient Saf, 2015, 41(11): 483-491. http://www.ncbi.nlm.nih.gov/pubmed/26484679
[14] RHODES A, EVANS L E, ALHAZZANI W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Crit Care Med, 2017, 45(3): 486-552.
[15] 钟娩玲, 黄宇戈. 早期乳酸测定联合儿童危重病例评分在重症监护室脓毒症患儿预后评估中的作用[J]. 中华实用儿科临床杂志, 2019, 34(12): 934-937. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_syeklczz201912017?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Wanfang_Med_Online_TrendMD_1 [16] LAMPING F, JACK T, RVBSAMEN N, et al. Development and validation of a diagnostic model for early differentiation of Sepsis and non-infectious SIRS in critically ill children-a data-driven approach using machine-learning algorithms[J]. BMC Pediatr, 2018, 18(1): 112. doi: 10.1186/s12887-018-1082-2
[17] 中华医学会儿科学分会医院感染管理与控制专业委员会. 血清降钙素原检测在儿童感染性疾病中的临床应用专家共识[J]. 中华儿科杂志, 2019, 57(1): 9-15. doi: 10.3760/cma.j.issn.0578-1310.2019.01.005 [18] BOUCHON A, FACCHETTI F, WEIGAND M A, et al. TREM-1 amplifies inflammation and is a crucial mediator of septic shock[J]. Nature, 2001, 410(6832): 1103-1107. doi: 10.1038/35074114
[19] BELLOS I, FITROU G, DASKALAKIS G, et al. Soluble TREM-1 as a predictive factor of neonatal sepsis: a meta-analysis[J]. Inflamm Res, 2018, 67(7): 571-578. doi: 10.1007/s00011-018-1149-4
[20] CHARLES P E, NOEL R, MASSIN F, et al. Significance of soluble triggering receptor expressed on myeloid cells-1 elevation in patients admitted to the intensive care unit with Sepsis[J]. BMC Infect Dis, 2016, 16(1): 559. doi: 10.1186/s12879-016-1893-4
[21] 刘雪燕, 吴伟元, 江意春, 等. 血清sTREM-1对脓毒症诊断及预后评估中的价值研究[J]. 中国急救医学, 2017, 37(12): 1091-1095. doi: 10.3969/j.issn.1002-1949.2017.12.005 [22] 肖婷, 陈丽萍, 黄晓华, 等. sCD14-ST在儿童脓毒症早期诊断中的应用[J]. 中华检验医学杂志, 2016, 39(4): 251-255. doi: 10.3760/cma.j.issn.1009-9158.2016.04.005 [23] KUMAR A, ROBERTS D, WOOD K E, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock[J]. Crit Care Med, 2006, 34(6): 1589-1596. doi: 10.1097/01.CCM.0000217961.75225.E9
[24] SEMLER M W, SELF W H, WANDERER J P, et al. SMART Investigators and the Pragmatic Critical Care Research Group: Balanced crystalloids versus saline in critically ill adults[J]. N Engl J Med, 2018, 378: 829-839. doi: 10.1056/NEJMoa1711584
[25] WEISS S L, KEELE L, BALAMUTH F, et al. Crystalloid fluid choice and clinical outcomes in pediatric sepsis: a matched retrospective cohort study[J]. J Pediatr, 2017, 182: 304-310.e10. doi: 10.1016/j.jpeds.2016.11.075
[26] EMRATH E T, FORTENBERRY J D, TRAVERS C, et al. Resuscitation with balanced fluids is associated with improved survival in pediatric severe Sepsis[J]. Crit Care Med, 2017, 45(7): 1177-1183. http://europepmc.org/abstract/MED/28437373
[27] MALBRAIN M L N G, VAN REGENMORTEL N, SAUGEL B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D's and the four phases of fluid therapy[J]. Ann Intensive Care, 2018, 8(1): 66. http://www.biomedcentral.com/openurl?doi=10.1186/s13613-018-0402-x
[28] RANJIT S, ARAM G, KISSOON N, et al. Multimodal monitoring for hemodynamic categorization and management of pediatric septic shock: a pilot observational study[J]. Pediatr Crit Care Med, 2014, 15(1): e17-e26. http://europepmc.org/abstract/med/24196006
[29] PHAM T, BROCHARD L J, SLUTSKY A S. Mechanical ventilation: state of the art[J]. Mayo Clin Proc, 2017, 92(9): 1382-1400. http://europepmc.org/abstract/MED/28870355
[30] 中华医学会儿科学分会急救学组, 中华医学会急诊医学分会儿科学组, 中国医师协会儿童重症医师分会. 中国儿童重症监护病房镇痛和镇静治疗专家共识(2018版)[J]. 中华儿科杂志, 2019, 57(5): 324-330. doi: 10.3760/cma.j.issn.0578-1310.2019.05.002 [31] FRANCOIS B, JEANNET R, DAIX T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial[J]. JCI Insight, 2018, 3(5): e98960. http://www.ncbi.nlm.nih.gov/pubmed/29515037
[32] HOTCHKISS R S, COLSTON E, YENDE S, et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)[J]. Crit Care Med, 2019, 47(5): 632-642. http://journals.lww.com/ccmjournal/Abstract/onlinefirst/Immune_Checkpoint_Inhibition_in_Sepsis__A_Phase_1b.96017.aspx
[33] LENIHAN D J, ANDERSON S A, LENNEMAN C G, et al. A phase I, single ascending dose study of cimaglermin Alfa (neuregulin 1β3) in patients with systolic dysfunction and heart failure[J]. JACC Basic Transl Sci, 2016, 1(7): 576-586. http://www.sciencedirect.com/science/article/pii/S2452302X16301619
[34] IACI J F, PARRY T J, HUANG Z, et al. An optimized dosing regimen of cimaglermin (neuregulin 1β3, glial growth factor 2) enhances molecular markers of neuroplasticity and functional recovery after permanent ischemic stroke in rats[J]. J Neurosci Res, 2016, 94(3): 253-265. doi: 10.1002/jnr.23699
[35] MOSEDALE M, BUTTON D, JACKSON J P, et al. Transient changes in hepatic physiology that alter bilirubin and bile acid transport may explain elevations in liver chemistries observed in clinical trials of GGF2(cimaglermin Alfa)[J]. Toxicol Sci, 2018, 161(2): 401-411. http://www.ncbi.nlm.nih.gov/pubmed/29069498
-
期刊类型引用(13)
1. 刘倩. 难治性胃食管反流病的中医疗法研究近况. 湖北中医杂志. 2023(11): 63-66 . 
百度学术
2. 杨超，陈莉丽，杨振斌. 方晓华抑木扶土法临床运用验案举隅. 中国民间疗法. 2022(14): 105-108 . 百度学术
3. 郭丽，夏军权，刘晓桐. 难治性胃食管反流病中医药诊治研究进展. 光明中医. 2021(22): 3790-3793 . 百度学术
4. 贾军峰，李文萍. 和胃降逆饮联合西药及针刺治疗残胃引起的反流性食管炎的疗效及对血清胃动素的影响. 中国中西医结合消化杂志. 2020(12): 944-948 . 百度学术
5. 刘妍. 疏肝降逆汤联合中医特色护理治疗胃食管反流病效果研究. 药品评价. 2019(01): 44-46 . 百度学术
6. 马雪梅. 和胃降逆汤加减联合奥美拉唑、枸橼酸莫沙必利治疗肝胃郁热型胃食管反流病的临床观察. 中国民间疗法. 2019(05): 55-56 . 百度学术
7. 房晓娜. 和胃降逆汤加减治疗胃食管反流病肝胃郁热型临床观察. 实用中医药杂志. 2019(04): 413-414 . 百度学术
8. 邓粉会. 自拟和胃降逆汤辅助西药治疗胃食管反流病相关性支气管哮喘疗效观察. 人人健康. 2019(24): 114-115 . 百度学术
9. 黄太伟. 半夏厚朴汤加减治疗难治性胃食管反流病的疗效研究. 实用医技杂志. 2018(06): 625-626 . 百度学术
10. 高钟. 泮托拉唑、香砂养胃丸、左金丸联用治疗胃食管反流病的效果观察. 中国社区医师. 2018(19): 102-103 . 百度学术
11. 姚向东. 雷贝拉唑、莫沙必利与玄麦甘桔三联用药治疗咽喉反流疾病的临床疗效. 中国合理用药探索. 2018(02): 8-11 . 百度学术
12. 王巧凤，王胜业. 和胃降逆汤加减治疗肝胃郁热型胃食管反流病疗效观察. 北方药学. 2018(11): 131 . 百度学术
13. 王茜茜，李华岳. 加减乌梅丸方联合穴位针刺对胃食管反流病患者食管动力的影响. 中国中医药现代远程教育. 2018(23): 42-44 . 百度学术
其他类型引用(7)
计量
- 文章访问数: 438
- HTML全文浏览量: 248
- PDF下载量: 74
- 被引次数: 20
下载:
苏公网安备 32100302010246号
